{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:25:57Z","timestamp":1792664757921,"version":"4.5.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijo.ijo_663_19","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T23:13:33Z","timestamp":1574723613000},"page":"2071","source":"Crossref","is-referenced-by-count":27,"title":["Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy"],"prefix":"10.4103","volume":"67","author":[{"given":"CarolL","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SaraE","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaurenA","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MarlanaM","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.271392-1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ophtha.2010.06.021","article-title":"Conjunctival melanoma.Outcomes based on tumor origin in 382 consecutive cases","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.271392-2","unstructured":"Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA. Conjunctival tumors: Review of clinical features, risks, biomarkers, and outcomes. The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol 2017;6:109-20."},{"key":"key-10.4103\/0301-4738.271392-3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.271392-4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0301-4738.271392-5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1758834017708160","article-title":"Treatment of NRAS-mutated advanced or metastatic melanoma: Rationale, current trials and evidence to date","author":"Boespflug","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"key-10.4103\/0301-4738.271392-6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:40:08Z","timestamp":1786732808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_663_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"alternative-id":["271392"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_663_19","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}